<DOC>
	<DOCNO>NCT00591149</DOCNO>
	<brief_summary>A study Oxaliplatin Docetaxel follow Cetuximab head neck cancer patient determine effect control reduction tumor size</brief_summary>
	<brief_title>Oxaliplatin Docetaxel Followed Cetuximab Head Neck Cancer</brief_title>
	<detailed_description>This non-randomized , open-label , phase II study ass effect oxaliplatin docetaxel follow epidermal factor-antibody ( EGFR-AB ) cetuximab patient previously treat recurrent /metastatic squamous cell carcinoma head neck . Head neck tissue also test determine protein Epidermal Growth Factor Receptor present cancer cell .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically confirm recurrent SCCHN 18 year old Tumor site accessible biopsy Measurable disease Receiving therapy ECOG performance status 01 Adequate bone marrow , renal function hepatic function Active infection fever within 3 day treatment Active CNS metastases Prior malignancy within 5 year Hypersensitivity study drug Chemotherapy within 30 day treatment Concurrent investigational therapy within 30 day Radiotherapy 25 % bone marrow Peripheral neuropathy grade 2 great Pregnant lactate patient History allogeneic transplant Active previously treat HIV Hepatitis B C Patients tracheostomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>squamous cell cancer</keyword>
</DOC>